Schlafen 11 assessment in high-grade serous ovarian carcinoma phenotypic and histological distribution

Domenico Ferraioli, Leonardo Peñuela, Anna Garuti, Chiara Carrozzi, Timothee Olivier, Bruno Spina, Sandra Salvi, Simone Ferrero, Jean Christophe Tille, Sana Intidhar Labidi-Galy, Gabriella Cirmena, Alberto Ballestero, Nicolas Chopin, Frederic Beurrier, Isabelle Treilleux, Isabelle Ray-Coquard, Gabriele Zoppoli, Valerio Gaetano Vellone

Research output: Contribution to journal › Article

Abstract

OBJECTIVE: To develop a protocol for immunohistochemistry (IHC) to determine the Schlafen 11 (SLFN11) expression in formalinfixed, paraffinembedded (FFPE) highgrade serous ovarian carcinoma (HGSOC) samples. STUDY DESIGN: We validated a reliable SLFN11 antibody (SLFN11Ab) in IHC choosing between 2 antiSLFN11Abs used for western blot through the development of a SLFN11IHC protocol in culture cell block (CCB) of ovarian carcinoma and in an HGSOC tissue microarray (TMA) series. We applied our protocol to a case series of HGSOC samples to confirm our preliminary results. For each case we evaluated both the intensity score (IS) and the distribution score (DS). A final histological score (HS) was obtained as follows: HS=IS×DS. RESULTS: In CCB and TMA series, the antibody #1 at 1:100 dilution was more reliable. This last one was used in our case series to confirm our IHC protocol. DS showed the following results: 27 cases were no stain, 11 cases showed staining for SLFN11 in <10% of cells, 16 cases showed staining in 10–40% of cells, and the remaining 15 cases showed stain in >40% of cells. IS showed the following results: 25 cases were no stain, in 19 cases a dominant weak stain, in 14 cases a moderate stain, and in 11 cases a strong stain. HS for SLFN11 expression presents a normal distribution with a prevalent (≈60%) intermediate expression. CONCLUSION: We develop a reproducible and standardized IHC protocol to determinate the SLFN11 expression in FFPE HGSOC samples using a modified western blot antiSLFN11Ab.

Original languageEnglish
Pages (from-to)222-230
Number of pages9
JournalAnalytical and Quantitative Cytopathology and Histopathology
Volume40
Issue number5
Publication statusPublished - Oct 1 2018

Fingerprint

Coloring Agents
Carcinoma
Immunohistochemistry
Cell Culture Techniques
Western Blotting
Antibodies
Normal Distribution
Staining and Labeling
Cells
Case Series

Keywords

  • Anti-SLFN11 antibody
  • Histological score
  • Immunohistochemistry
  • Ovarian cancer
  • Ovarian neoplasms
  • Schlafen-11
  • Serous high grade ovarian cancer.
  • SLFN11

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine
  • Cell Biology

Cite this

Schlafen 11 assessment in high-grade serous ovarian carcinoma phenotypic and histological distribution. / Ferraioli, Domenico; Peñuela, Leonardo; Garuti, Anna; Carrozzi, Chiara; Olivier, Timothee; Spina, Bruno; Salvi, Sandra; Ferrero, Simone; Tille, Jean Christophe; Labidi-Galy, Sana Intidhar; Cirmena, Gabriella; Ballestero, Alberto; Chopin, Nicolas; Beurrier, Frederic; Treilleux, Isabelle; Ray-Coquard, Isabelle; Zoppoli, Gabriele; Vellone, Valerio Gaetano.

In: Analytical and Quantitative Cytopathology and Histopathology, Vol. 40, No. 5, 01.10.2018, p. 222-230.

Research output: Contribution to journal › Article

Ferraioli, D, Peñuela, L, Garuti, A, Carrozzi, C, Olivier, T, Spina, B, Salvi, S, Ferrero, S, Tille, JC, Labidi-Galy, SI, Cirmena, G, Ballestero, A, Chopin, N, Beurrier, F, Treilleux, I, Ray-Coquard, I, Zoppoli, G & Vellone, VG 2018, 'Schlafen 11 assessment in high-grade serous ovarian carcinoma phenotypic and histological distribution', Analytical and Quantitative Cytopathology and Histopathology, vol. 40, no. 5, pp. 222-230.
Ferraioli D, Peñuela L, Garuti A, Carrozzi C, Olivier T, Spina B et al. Schlafen 11 assessment in high-grade serous ovarian carcinoma phenotypic and histological distribution. Analytical and Quantitative Cytopathology and Histopathology. 2018 Oct 1;40(5):222-230.
Ferraioli, Domenico ; Peñuela, Leonardo ; Garuti, Anna ; Carrozzi, Chiara ; Olivier, Timothee ; Spina, Bruno ; Salvi, Sandra ; Ferrero, Simone ; Tille, Jean Christophe ; Labidi-Galy, Sana Intidhar ; Cirmena, Gabriella ; Ballestero, Alberto ; Chopin, Nicolas ; Beurrier, Frederic ; Treilleux, Isabelle ; Ray-Coquard, Isabelle ; Zoppoli, Gabriele ; Vellone, Valerio Gaetano. / Schlafen 11 assessment in high-grade serous ovarian carcinoma phenotypic and histological distribution. In: Analytical and Quantitative Cytopathology and Histopathology. 2018 ; Vol. 40, No. 5. pp. 222-230.
@article{6c729fbc9d094adda0e6b36b6c7b89d2,
title = "Schlafen 11 assessment in high-grade serous ovarian carcinoma phenotypic and histological distribution",
abstract = "OBJECTIVE: To develop a protocol for immunohistochemistry (IHC) to determine the Schlafen 11 (SLFN11) expression in formalinfixed, paraffinembedded (FFPE) highgrade serous ovarian carcinoma (HGSOC) samples. STUDY DESIGN: We validated a reliable SLFN11 antibody (SLFN11Ab) in IHC choosing between 2 antiSLFN11Abs used for western blot through the development of a SLFN11IHC protocol in culture cell block (CCB) of ovarian carcinoma and in an HGSOC tissue microarray (TMA) series. We applied our protocol to a case series of HGSOC samples to confirm our preliminary results. For each case we evaluated both the intensity score (IS) and the distribution score (DS). A final histological score (HS) was obtained as follows: HS=IS×DS. RESULTS: In CCB and TMA series, the antibody #1 at 1:100 dilution was more reliable. This last one was used in our case series to confirm our IHC protocol. DS showed the following results: 27 cases were no stain, 11 cases showed staining for SLFN11 in <10{\%} of cells, 16 cases showed staining in 10–40{\%} of cells, and the remaining 15 cases showed stain in >40{\%} of cells. IS showed the following results: 25 cases were no stain, in 19 cases a dominant weak stain, in 14 cases a moderate stain, and in 11 cases a strong stain. HS for SLFN11 expression presents a normal distribution with a prevalent (≈60{\%}) intermediate expression. CONCLUSION: We develop a reproducible and standardized IHC protocol to determinate the SLFN11 expression in FFPE HGSOC samples using a modified western blot antiSLFN11Ab.",
keywords = "Anti-SLFN11 antibody, Histological score, Immunohistochemistry, Ovarian cancer, Ovarian neoplasms, Schlafen-11, Serous high grade ovarian cancer., SLFN11",
author = "Domenico Ferraioli and Leonardo Pe{\~n}uela and Anna Garuti and Chiara Carrozzi and Timothee Olivier and Bruno Spina and Sandra Salvi and Simone Ferrero and Tille, {Jean Christophe} and Labidi-Galy, {Sana Intidhar} and Gabriella Cirmena and Alberto Ballestero and Nicolas Chopin and Frederic Beurrier and Isabelle Treilleux and Isabelle Ray-Coquard and Gabriele Zoppoli and Vellone, {Valerio Gaetano}",
year = "2018",
month = "10",
day = "1",
language = "English",
volume = "40",
pages = "222--230",
journal = "Bulletin of the John Rylands Library",
issn = "2054-9318",
publisher = "John Rylands University Library",
number = "5",

}

TY - JOUR

T1 - Schlafen 11 assessment in high-grade serous ovarian carcinoma phenotypic and histological distribution

AU - Ferraioli, Domenico

AU - Peñuela, Leonardo

AU - Garuti, Anna

AU - Carrozzi, Chiara

AU - Olivier, Timothee

AU - Spina, Bruno

AU - Salvi, Sandra

AU - Ferrero, Simone

AU - Tille, Jean Christophe

AU - Labidi-Galy, Sana Intidhar

AU - Cirmena, Gabriella

AU - Ballestero, Alberto

AU - Chopin, Nicolas

AU - Beurrier, Frederic

AU - Treilleux, Isabelle

AU - Ray-Coquard, Isabelle

AU - Zoppoli, Gabriele

AU - Vellone, Valerio Gaetano

PY - 2018/10/1

Y1 - 2018/10/1

N2 - OBJECTIVE: To develop a protocol for immunohistochemistry (IHC) to determine the Schlafen 11 (SLFN11) expression in formalinfixed, paraffinembedded (FFPE) highgrade serous ovarian carcinoma (HGSOC) samples. STUDY DESIGN: We validated a reliable SLFN11 antibody (SLFN11Ab) in IHC choosing between 2 antiSLFN11Abs used for western blot through the development of a SLFN11IHC protocol in culture cell block (CCB) of ovarian carcinoma and in an HGSOC tissue microarray (TMA) series. We applied our protocol to a case series of HGSOC samples to confirm our preliminary results. For each case we evaluated both the intensity score (IS) and the distribution score (DS). A final histological score (HS) was obtained as follows: HS=IS×DS. RESULTS: In CCB and TMA series, the antibody #1 at 1:100 dilution was more reliable. This last one was used in our case series to confirm our IHC protocol. DS showed the following results: 27 cases were no stain, 11 cases showed staining for SLFN11 in <10% of cells, 16 cases showed staining in 10–40% of cells, and the remaining 15 cases showed stain in >40% of cells. IS showed the following results: 25 cases were no stain, in 19 cases a dominant weak stain, in 14 cases a moderate stain, and in 11 cases a strong stain. HS for SLFN11 expression presents a normal distribution with a prevalent (≈60%) intermediate expression. CONCLUSION: We develop a reproducible and standardized IHC protocol to determinate the SLFN11 expression in FFPE HGSOC samples using a modified western blot antiSLFN11Ab.

AB - OBJECTIVE: To develop a protocol for immunohistochemistry (IHC) to determine the Schlafen 11 (SLFN11) expression in formalinfixed, paraffinembedded (FFPE) highgrade serous ovarian carcinoma (HGSOC) samples. STUDY DESIGN: We validated a reliable SLFN11 antibody (SLFN11Ab) in IHC choosing between 2 antiSLFN11Abs used for western blot through the development of a SLFN11IHC protocol in culture cell block (CCB) of ovarian carcinoma and in an HGSOC tissue microarray (TMA) series. We applied our protocol to a case series of HGSOC samples to confirm our preliminary results. For each case we evaluated both the intensity score (IS) and the distribution score (DS). A final histological score (HS) was obtained as follows: HS=IS×DS. RESULTS: In CCB and TMA series, the antibody #1 at 1:100 dilution was more reliable. This last one was used in our case series to confirm our IHC protocol. DS showed the following results: 27 cases were no stain, 11 cases showed staining for SLFN11 in <10% of cells, 16 cases showed staining in 10–40% of cells, and the remaining 15 cases showed stain in >40% of cells. IS showed the following results: 25 cases were no stain, in 19 cases a dominant weak stain, in 14 cases a moderate stain, and in 11 cases a strong stain. HS for SLFN11 expression presents a normal distribution with a prevalent (≈60%) intermediate expression. CONCLUSION: We develop a reproducible and standardized IHC protocol to determinate the SLFN11 expression in FFPE HGSOC samples using a modified western blot antiSLFN11Ab.

KW - Anti-SLFN11 antibody

KW - Histological score

KW - Immunohistochemistry

KW - Ovarian cancer

KW - Ovarian neoplasms

KW - Schlafen-11

KW - Serous high grade ovarian cancer.

KW - SLFN11

UR - http://www.scopus.com/inward/record.url?scp=85057314491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057314491&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85057314491

VL - 40

SP - 222

EP - 230

JO - Bulletin of the John Rylands Library

JF - Bulletin of the John Rylands Library

SN - 2054-9318

IS - 5

ER -

Access to Document